Search Details

Word: merck (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

Within the chemistry department, outside funding generally comes from large pharmaceutical companies such as Merck, Pfizer, Bristol-Myers Squibb and Hoffman-LaRoche...

Author: By Sasha A. Haines-stiles, CRIMSON STAFF WRITER | Title: Harvard Reviews Conflict-of-Interest Policies | 3/10/2000 | See Source »

...early days, the financial advice Giacchetto doled out was as stodgy as his social life was edgy. He spent hours poring over technical charts, and then steered his clients to blue chips like Merck and AT&T. But somewhere along the way, he was seduced by the adrenaline rush of higher risk. His Cassandra Group investment management company bet heavily on Iridium, the global telephone satellite firm that filed for bankruptcy last summer. He also invested in Paradise Music & Entertainment, which was paying him to serve as a consultant. (Giacchetto says he informed most of his clients of the arrangement...

Author: /time Magazine | Title: Falling Off The A-List | 12/20/1999 | See Source »

Other partners include pharmaceutical company Merck, Nippon Telegraph and Telephone Corporation, Merrill Lynch and DuPont...

Author: By Vasugi V. Ganeshananthan and Erica B. Levy, CRIMSON STAFF WRITERSS | Title: Harvard and MIT Face Off For Technology Funding | 10/19/1999 | See Source »

...medical literature and calling scientists. Eventually he talked to Dr. Randall Burt, now the chief of gastroenterology at the University of Utah. Coincidentally, Burt had just heard University of Colorado surgeon William Waddell tell a scientific meeting that he had seen an aspirin-like arthritis drug called sulindac (Merck) almost miraculously melt away colon polyps. The finding was anecdotal, observed in only a few patients, but it was just what Nichols wanted to hear...

Author: /time Magazine | Title: Cure Crusader | 10/11/1999 | See Source »

...expected to rise 21% for brand-name drugs, 8% for generic drugs. Some HMO's are also tightening annual caps for Medicare recipients: 32% of the plans will set the limit at $500 or less. That's up from 21% in 1999. Should investors dump big drug stocks like Merck? Analysts say the higher costs won't apply to enough consumers to hurt stock prices...

Author: /time Magazine | Title: In Brief: Oct. 4, 1999 | 10/4/1999 | See Source »

First | Previous | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | Next | Last